Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

SeDiBone Biomaterials Design through Machine Learning for Sex- and Disease-Specific Bone Regeneration

Coordinator
Stichting Radboud Universitair Medisch Centrum, Netherlands
Runs
1 June 2025 to 31 May 2027
Status
Running
EU funding
€203k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101154946

What the project is doing

In the project's own words, from its summary on CORDIS.

Osteoporosis, a widespread disease that causes bone fragility, currently afflicts over 32 million Europeans, with rapidly increasingprevalence expected due to population aging. The costs of therapies for osteoporotic fragility fractures total more than 50 billion peryear in the EU. Postmenopausal females are at especially increased risk for osteoporosis, and the regenerative capacity of healthybone also differs between the biological sexes.

Although biomaterials have been developed to aid bone regeneration after injury, the influence of biological sex and osteoporoticdisease have not been taken into account for such biomaterials design. Excitingly, the advent of machine learning (ML) offers thepotential to unravel the effects of sex and osteoporotic disease on biomaterials bone regenerative capacity, and to apply theseinsights to design biomaterials optimized to these characteristics.

Therefore, the SeDiBone project will for the first time exploit ML to elucidate the influence of sex and osteoporotic disease onbone regeneration, and to translate these insights towards design of an entirely new class of biomaterials with sex and osteoporoticspecificity. By enabling automated localization of tissue defect sites and detailed tissue, cell, and interface identification, SeDiBone will deliver an Analysis Tool that efficiently and reproducibly quantifies bone regeneration outcomes in male or female and healthy or osteoporotic preclinical animal models (Aim 1).

These in-depth insights will then serve as inputs for a Design Tool to determine the biomaterials designs correlating to optimal regenerative success based on sex and osteoporosis, with validation through ex vivo demonstration (Aim 2). SeDiBone will thus crucially synergize and advance efforts to design a new generation of patient-specific biomaterials, and accordingly inform therapeutic solutions for regeneration of bone tissue in the unexplored areas of sex- and disease-based specificity.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI